0001822929 false --12-31 00-0000000 0001822929 2022-10-25 2022-10-25 0001822929 eucr:OrdinarySharesnoparvalueMember 2022-10-25 2022-10-25 0001822929 us-gaap:WarrantMember 2022-10-25 2022-10-25 0001822929 eucr:UnitseachconsistingofoneOrdinarySharesandonethirdofonewarrantMember 2022-10-25 2022-10-25 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): October 25, 2022

 

Eucrates Biomedical Acquisition Corp.

(Exact name of registrant as specified in its charter)

 

British Virgin Islands   001-39650   N/A
(State or other jurisdiction   (Commission   (IRS Employer
of incorporation)   File Number)   Identification No.)

 

250 West 55th Street, Suite 13D

New York, New York 10019

(Address of principal executive offices, including zip code)

 

Registrant’s telephone number, including area code: 212-710-5220

 

Not Applicable

(Former name or former address, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class:  

Trading
Symbols

 

Name of Each Exchange on Which
Registered:

Ordinary shares, no par value   EUCR   Nasdaq Capital Market
Warrants, each whole warrant exercisable for one ordinary share at an exercise price of $11.50 per share   EUCRW   Nasdaq Capital Market
Units, each consisting of one Ordinary Shares and one-third of one warrant   EUCRU   Nasdaq Capital Market

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

 

On October 25, 2022, Eucrates Biomedical Acquisition Corp. (the “Company”) held a special meeting (the “Special Meeting”) of shareholders in lieu of the 2022 annual general meeting of shareholders. At the Special Meeting, the Company’s shareholders approved an amendment to the Amended and Restated Memorandum and Articles of Association (the “Amended Charter”) to extend the date by which the Company must consummate a business combination from October 27, 2022 to April 27, 2023. On October 25, 2022, the Company filed the Amended Charter with the Registry of Corporate Affairs in the British Virgin Islands.

 

The foregoing description is qualified in its entirety by reference to the Amended Charter, a copy of which is attached as Exhibit 3.1 hereto and is incorporated by reference herein.

 

Item 9.01 Financial Statements and Exhibits

 

(d) Exhibits

 

Exhibit

Number

  Description
3.1   Amendment to the Amended and Restated Memorandum and Articles of Association
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: October 31, 2022

 

  EUCRATES BIOMEDICAL ACQUISITION CORP.
   
  By: /s/ Gonzalo Cordova
    Name: Gonzalo Cordova
    Title: Chief Financial Officer

 

 

 

 

Eucrates Biomedical Acqu... (NASDAQ:EUCR)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Eucrates Biomedical Acqu... Charts.
Eucrates Biomedical Acqu... (NASDAQ:EUCR)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Eucrates Biomedical Acqu... Charts.